EANS-Adhoc: LifeWatch Services, Inc. Launches Stroke Patient Care Program

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products

09.09.2009

LifeWatch AG´s (SIX Swiss Exchange: LIFE) American subsidiary
LifeWatch Services, Inc., the leading provider of wireless
telemedicine services in the U.S., announced the launch of its Stroke
Patient Care program for monitoring patients who have experienced a
Transient Ischemic Attacks(TIA)/Stroke of unknown origin
(cryptogenic).

Stroke is the third leading cause of death in the United States. Each
year approximately 795,000 Americans will suffer a new or recurrent
stroke, which on average, means that a stroke will occur every 40
seconds. A Transient Ischemic Attack (TIA) is defined as a brief
episode in which the brain gets insufficient blood supply and
described as an incomplete stroke whose symptoms typically last for
minutes up to a few hours. One third of individuals who have had one
or more TIAs will suffer a stroke. With 36% of those who survive such
an event, the cause is unknown or cryptogenic. Furthermore, multiple
clinical trials have demonstrated the efficacy of chronic oral
anticoagulation (Coumadin) in patients who are at high risk for
recurrent embolic neurological events. However, Coumadin is not
without risk and requires accurate diagnosis of Paroxysmal Atrial
Fibrillation (PAF) before the initiation of therapy. A recent study
demonstrates that outpatient cardiac telemetry can detect
asymptomatic (no symptoms) Atrial Fibrillation (AF) in up to 23% of
patients who have experienced a stroke or TIA of unknown origin. AF
episodes as brief as 30 seconds may indicate more prolonged and
clinically significant AF.1 A specialized Stroke Patient Care program
utilizing LifeStar ACT technology to detect asymptomatic AF has the
ability to accurately identify the cause of stroke and reduce the
possibility of long term catastrophic effects.

"To significantly decrease the incidence of secondary stroke,
physicians treating these patients need a convenient monitoring
solution to identify stroke patients with abnormal heart rhythms but
no symptoms", stated Leigh Ann Kelly, Vice President of Business
Development at LifeWatch. "LifeWatch´s Medical Advisory Board and
senior clinicians have collaborated extensively with renowned stroke
specialists and neurologists in order to develop a monitoring program
that meets the needs of both stroke patients and their treating
physicians".

"Cryptogenic stroke is more common in the geriatric population, yet
most cardiac event looping recorders present technological challenges
for these patients, in particular with those who have a neurologic
deficit", stated Harry Kopelman, M.D., LifeWatch Medical Advisory
Board Chairman. "The ACT III cardiac telemetry device is a better
choice as a diagnostic tool with a dedicated disease management
program, as it can lead to more accurate and efficient arrhythmia
diagnosis which is critical to the management of the cryptogenic
stroke population".

"The LifeWatch Stroke Patient Care program will be supported by the
ACT service platform and is the second patient care program that we
have launched in the past 18 months", stated Dr. Yacov Geva, Chairman
and CEO of LifeWatch AG, adding "This latest expansion will enable us
to pursue our mission of improving patient care and outcomes".

1. Tayal et al, Neurology 2008.

About LifeWatch AG LifeWatch AG, headquartered in Neuhausen am
Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is
the leading healthcare technology and solution company, specializing
in advanced telehealth systems and wireless cardiac monitoring
services. LifeWatch services treat high-risk and chronically ill
patients, health conscious consumers and wellness programs. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology
products. www.lifewatch.com

Sign-up for customized e-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these forward
looking statements largely on current expectations and projections
about future events and financial trends that it believes may affect
the financial condition, results of operations, business strategy,
short term and long term business operations and objectives, and
financial needs. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions. In light of these
risks, uncertainties and assumptions, the forward-looking events and
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based
only on data available to LifeWatch AG at the time of the issue of
this press release. LifeWatch AG does not undertake any obligation to
update any forward-looking statements contained in this press release
as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

For further information please contact:

Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG

Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Europe

Sensus Investor and Public Relations GmbH, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch

USA

Westwicke Partners

asher.dewhurst@westwicke.com

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade